Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

China’s AI is future of R&D leading the globe, aiding in healthcare, and spurring economic growth

Shen et al ’22 (Responsible for 4x China Analytics practice to ~100 data scientists, developers and business translators in ~2 years, “The next frontier for AI in China could add $600 billion to its economy,” QuantumBlack AI by McKinsey, 6/7/22) https://www.mckinsey.com/business-functions/quantumblack/our-insights/the-next-frontier-for-ai-in-china-could-add-600-billion-to-its-economy

Healthcare and life sciences: In recent years, China has stepped up its investment in innovation in healthcare and life sciences with AI. China’s “14th Five-Year Plan” targets 7 percent annual growth by 2025 for R&D expenditure, of which at least 8 percent is devoted to basic research. 13 One area of focus is accelerating drug discovery and increasing the odds of success, which is a significant global issue. In 2021, global pharma R&D spend reached $212 billion, compared with $137 billion in 2012, with an approximately 5 percent compound annual growth rate (CAGR). Drug discovery takes 5.5 years on average, which not only delays patients’ access to innovative therapeutics but also shortens the patent protection period that rewards innovation. Despite improved success rates for new-drug development, only the top 20 percent of pharmaceutical companies worldwide realized a breakeven on their R&D investments after seven years. Another top priority is improving patient care, and Chinese AI start-ups today are working to build the country’s reputation for providing more accurate and reliable healthcare in terms of diagnostic outcomes and clinical decisions. Our research suggests that AI in R&D could add more than $25 billion in economic value in three specific areas: faster drug discovery, clinical-trial optimization, and clinical-decision support. Rapid drug discovery. Novel drugs (patented prescription drugs) currently account for less than 30 percent of the total market size in China (compared with more than 70 percent globally), indicating a significant opportunity from introducing novel drugs empowered by AI in discovery. We estimate that using AI to accelerate target identification and novel molecules design could contribute up to $10 billion in value. 14 Already more than 20 AI start-ups in China funded by private-equity firms or local hyperscalers are collaborating with traditional pharmaceutical companies or independently working to develop novel therapeutics. Insilico Medicine, by using an end-to-end generative AI engine for target identification, molecule design, and lead optimization, discovered a preclinical candidate for pulmonary fibrosis in less than 18 months at a cost of under $3 million. This represented a significant reduction from the average timeline of six years and an average cost of more than $18 million from target discovery to preclinical candidate. This antifibrotic drug candidate has now successfully completed a Phase 0 clinical study and entered a Phase I clinical trial. Clinical-trial optimization. Our research suggests that another $10 billion in economic value could result from optimizing clinical-study designs (process, protocols, sites), optimizing trial delivery and execution (hybrid trial-delivery model), and generating real-world evidence. 15 These AI use cases can reduce the time and cost of clinical-trial development, provide a better experience for patients and healthcare professionals, and enable higher quality and compliance. For instance, a global top 20 pharmaceutical company leveraged AI in combination with process improvements to reduce the clinical-trial enrollment timeline by 13 percent and save 10 to 15 percent in external costs. The global pharmaceutical company prioritized three areas for its tech-enabled clinical-trial development. To accelerate trial design and operational planning, it utilized the power of both internal and external data for optimizing protocol design and site selection. For streamlining site and patient engagement, it established an ecosystem with API standards to leverage internal and external innovations. To establish a clinical-trial development cockpit, it aggregated and visualized operational trial data to enable end-to-end clinical-trial operations with full transparency so it could predict potential risks and trial delays and proactively take action. The future of AI in China: Clinical-decision support. Our findings indicate that the use of machine learning algorithms on medical images and data (including examination results and symptom reports) to predict diagnostic outcomes and support clinical decisions could generate around $5 billion in economic value. 16 A leading AI start-up in medical imaging now applies computer vision and machine learning algorithms on optical coherence tomography results from retinal images. It automatically searches and identifies the signs of dozens of chronic illnesses and conditions, such as diabetes, hypertension, and arteriosclerosis, expediting the diagnosis process and increasing early detection of disease.

Sign in to recut, update, or save this card.